a Clinical Study.the Effect of Addition of Insoluble Antibacterial Nanoparticles(IABN) in Resin Base Provisional Cement (IABN)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Hadassah Medical Organization.
Recruitment status was  Active, not recruiting
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
First received: July 16, 2007
Last updated: January 5, 2010
Last verified: October 2009

The effect of Antibacterial Nanoparticles, Incorporated in cement, on S.mutans in the margins of provisional restorations is going to be examined clinically by using two kinds of provisional cement 1. cement with out antibacterial nanoparticles.

2.cement with small addition of IABN. after one week in the mouth the crowns are to be removed and examined for the presence and quantity of s. mutans. in vitro tests of the same has shown significant reduction in bacterial population around the provisional cement as compared to the regular cement.

Oral Rehabilitaiton

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Clinical Study :The Effect of Antibacterial Nanoparticles, Incorporated in Provisional Resin Based Cement, on S.Mutans in the Margins of Provisional Restorations

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Enrollment: 10
Study Start Date: February 2007
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
patients with provisional crowns
the same patient would serve as control and test

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
hadassah dental patients

Inclusion Criteria:

  • Patients who need provisional restorations.

Exclusion Criteria:

  • Patients who got antibacterial therapy in the past 3 months.
  • Patients using chlorhexidine gluconate.
  • Pregnant women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00502606

Hadassah Medical Organization,
Jerusalem,, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Michael Perez Davidi, DMD Hadassah Medical Organization
Study Director: Nir Sterer, DMD PhD Hadassah Medical Organization
Study Chair: Ervin Weiss, DMD Hadassah Medical Organization
  More Information

Responsible Party: Ervin Weiss, Hadassah Medical Centers
ClinicalTrials.gov Identifier: NCT00502606     History of Changes
Other Study ID Numbers: 191061HMO-CTIL 
Study First Received: July 16, 2007
Last Updated: January 5, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
provisional restoration
antibacterial nanoparticles

Additional relevant MeSH terms:
Mouth Diseases
Periodontal Diseases
Stomatognathic Diseases
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on May 24, 2016